Pilot-Feasibility Core for Rare Lung Diseases
Official title: Pilot-Feasibility Core
Funded at University of Cincinnati · NIH-11453393 · Data updated 2026-11-12
A funded program that supports small, patient-focused pilot studies to speed up finding better ways to diagnose and treat rare lung diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | September 5, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $36,408 |
| NIH project number | 1U54HL188781-01 |
| Project ID | NIH-11453393 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with rare lung diseases who may participate in future pilot studies or benefit from improved disease understanding and care pathways.
✕Less likely to help
Individuals without a rare lung disease or those not involved in pilot projects may not directly benefit.
What this research studies
This grant backs the RLDC Pilot Project Core, which funds short, focused studies to answer key clinical questions. It aims to speed up clinical trial readiness and improve patient care in rare lung diseases. It also builds infrastructure, standardizes data collection, and connects patients with researchers across sites. The program encourages new investigators to join the field and collaborate with patient communities to advance meaningful outcomes.
Why it matters
Potential benefit: If successful, it could accelerate the development of better diagnostic tools and treatments for people with rare lung diseases.
How similar studies have gone: Pilot and multicenter collaborations have shown that structured pilot projects can accelerate trial readiness in complex diseases.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Kropski, Jonathan Andrew — University of Cincinnati
- Study coordinator: Kropski, Jonathan Andrew
Related research
Other NIH-funded projects on the same topics.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
-
MnSOD modification drives a stem-cell like switch in some ER-positive breast cancers
A small study in ER-positive breast cancer looks at how a specific mitochondrial change (MnSOD-K68 acetylation) may push cancer cells toward a more stem-like, therapy-resistant state.
-
Lineage changes in cancer cells drive resistance to radiation and hormone therapy
A cancer-focused study looks at how a mitochondrial enzyme modification may cause tumor cells to resist radiation and hormone therapy in prostate cancer.
-
Repurposed Antiretroviral Therapies to Eliminate Cervical Cancer
A pilot study tests a self-administered vaginal capsule with protease inhibitors to safely treat cervical precancer (CIN 2/3) in women, using a non-invasive approach.
-
Recombinant factor VIIa given very early for bleeding stroke
This trial gives a clotting medicine called rFVIIa very soon after a spontaneous brain bleed to adults to try to improve recovery.
-
Early Factor VIIa treatment for bleeding stroke
This project tests whether giving a clotting medicine called recombinant Factor VIIa very soon after a spontaneous brain bleed helps adults recover better than standard care alone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.